Our commitments to patients

We will report on our progress towards achieving these commitments annually, and update them to reflect patient needs, as we work to bring COMP360 psilocybin therapy to everyone who might benefit from it.

Safety

COMPASS is committed to keeping patients safe

We are committed to keeping patients safe at every step of their therapeutic journey. We will work to achieve this by developing therapies that have been tested rigorously for their safety and efficacy in large-scale clinical trials, and by recruiting capable and compassionate therapists who are motivated to help patients, and training them to always prioritise patient wellbeing and care.

Access

COMPASS is committed to making COMP360 psilocybin therapy available to as many people as possible

We are committed to developing evidence-based innovations, whilst developing access and pricing strategies that prioritise affordability and accessibility. We are working closely with payors, patient advocacy groups, healthcare systems and regulators to understand how we make our therapies available to everyone who might benefit from them.

Transparency

COMPASS is committed to sharing our research in ways that patients can understand

Once published in a peer-reviewed journal, we will ensure open access to our research findings, making it available for everyone to read free of charge. We are committed to sharing the results of this research on our website, in plain language, in a timely and accessible manner, so that patients can understand it.

Inclusion

COMPASS is committed to listening to patients

We will establish a series of independent patient panels, made up of patients and their caregivers, and representing a range of experiences, demographics, and geographies. We commit to seeking patient input as we develop innovations in mental health care - so that our actions are informed by patient voices.